AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04464746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: implementation of a specific program to improve therapeutic adherence
Description: 1. Discussion of risks associated with high BP;aims,healthy lifestyle options.~2. Individualized educational intervention:verbal, written,audiovisual information. Evaluation of knowledge of prescribed drugs.~3. Behavioral counseling.training patients to participate in their own care, while positively modifying their skills or routines (i.e. pill boxes,calendars,specific measures to remind the patient taking drugs,adapt the regimen to atient's daily routine).~4. Socio-psycho-affective interventions.~5. Reminder systems: phone,email,alarm on the mobile phone.~6. Simplification as far as possible of therapeutic scheme.~7. Explanation of prescribed medications (name\&dosage), correct intake.~8. Explanation of possible side effects and what to do if they happen. Facilitate a contact.~9. Advise and training on home blood pressure self-measurement.~10. Verbal, written and/or audiovisual information and the online patients'section of scientific societies addresses will be provided.
Study NCT03308604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polysiloxane Gd-Chelates based nanoparticles (AGuIX)
Description: Three intravenous injections of AGuIX will be delivered.~The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.~Irradiation will be performed after the second MRI.~The second injection will be followed by an MRI 4 hours later.~The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.~Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg.
Study NCT03308604 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT)
Description: to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases
Study NCT03308604 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Uterovaginal brachytherapy
Description: 15 Gy (maximal interval between EBRT and brachytherapy: 14 days).
Study NCT03308604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin)
Description: Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
Study NCT00134966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Study NCT00134966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Study NCT03835507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: recombinant human erythropoietin(rhEPO)
Description: Injection of erythropoietin every months (total 12 months)
Study NCT03835507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin(rhEPO)
Description: Injection of erythropoietin every months (total 12 months)
Study NCT01466075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Evolution Investigational BG Monitoring System
Description: Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and Alternative Site Testing (AST) of the palm using the Apollo Evolution meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects complete basic tasks using the User Guide and provide feedback.
Study NCT00391872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
Study NCT00391872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily dose (ODD)
Study NCT02484092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPK-9001
Description: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
Study NCT00215644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matuzumab
Description: Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
Study NCT00215644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
Study NCT00215644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
Study NCT00215644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
Study NCT00215644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
Study NCT00215644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.
Study NCT00215644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.
Study NCT03089645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5083 monotherapy
Description: Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab
Study NCT03089645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEID5083 with Durvalumab or Tremelimumab
Description: Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab
Study NCT03089645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medi5083 with Durvalumab and Docetaxel
Description: Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel
Study NCT03701438 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine
Description: Administered per standard of care using a vaccine licensed and recommended in the site's country
Study NCT00447551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-L-Lactic Acid
Description: Deep dermal injection
Study NCT03559751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLN cigarettes (A)
Description: 0.4mg nicotine / g tobacco king size filter cigarette
Study NCT03559751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Brand Cigarettes (B)
Description: Usual brand king size non-menthol cigarettes
Study NCT03559751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum (C)
Description: 4 mg nicotine gum
Study NCT03746405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: excitatory 5Hz rTMS will be used
Study NCT03746405 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
Study NCT00540839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Description: Montelukast 4 mg OG or montelukast 4 mg CT
Study NCT00540839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to montelukast
Description: Placebo OG or CT
Study NCT00540839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone 50 mcg inhalation aerosol metered dose inhaler
Study NCT00540839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to fluticasone
Description: Placebo inhalation aerosol metered dose inhaler
Study NCT02793219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Study NCT02793219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02778035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsomedial prefrontal rTMS
Description: Dorsomedial prefrontal rTMS, bilateral, iTBS, 600 pulses per hemisphere, 120% RMT, 2 sessions at 0, 30, or 60 min inter-session interval
Study NCT03063619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimoxifene
Description: Applied topically
Study NCT03063619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03063619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03063619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applied topically
Study NCT03063619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03063619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00308516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15
Study NCT00308516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15
Study NCT00308516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: radiation 1.8 Gy/day or 28 fractions weeks 1-6
Study NCT00308516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15
Study NCT00308516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15
Study NCT03290118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Rating System - Traffic Light
Description: Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage, by indicating the levels (low=green, moderate=amber, high=red) of sodium, saturated fat and sugar in a product based on modified Food Standards Australia New Zealand (FSANZ) criteria.
Study NCT03290118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Rating System - Health Star
Description: Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating the number of stars awarded to a product, from 0.5 to 5 stars, based on modified Food Standards Australia New Zealand (FSANZ) nutrient profiling criteria.
Study NCT03290118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Rating System - Warning Label
Description: Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating with a warning label products that are high in sodium, saturated fat and sugar, based on a percent daily value (%DV) greater than 15% for individual products and 30% for combination dishes.
Study NCT03290118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone application FoodFlip Device®
Description: This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.
Study NCT02065401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferitazole (disodium salt, granule)
Description: Single oral dose of 1500 mg administered on Day 1
Study NCT02065401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferitazole (disodium salt, tablet)
Description: Single oral dose of 1500 mg administered on Day 1
Study NCT02446132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Study NCT02065401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferitazole (magnesium hydroxide salt)
Description: Single oral dose of 2400 mg administered on Day 1
Study NCT02581488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Santyl
Study NCT02581488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product containing silver
Description: Silver product not specified by the protocol; Investigators choose the appropriate silver containing product for each diabetic foot ulcer
Study NCT01594918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 25 mg/m2 or 20 mg/m2, IV, once every 21 days
Study NCT01594918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
Study NCT01594918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg PO BID
Study NCT01594918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg, SC, once every 21 days
Study NCT02991469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study NCT04403555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin treatment
Study NCT01075997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cell phone delivered tele-educational
Description: This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone.
Study NCT01075997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cell phone
Description: This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider. The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
Study NCT01360788 — intervention group
Intervention type: DRUG
Intervention: Combination ipratropium/salbutamol or placebo (nebulization)
Description: The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
Study NCT04143711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.
Study NCT02637310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N02RS1 1200mg
Description: 1200mg/day, Three times a day orally, 2 tablets once, 7 days
Study NCT02637310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1200mg/day, Three times a day orally, 2 tablets once, 7 days
Study NCT01443741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic education
Description: Specific program for FIT Therapy and specific program for traditional way
Study NCT00536770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + gemcitabine + erlotinib
Study NCT00536770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + gemcitabine
Study NCT00536770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcitriol + gemcitabine
Study NCT00536770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcitriol + gemcitabine + erlotinib
Study NCT04346407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5mg Cap
Description: 2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
Study NCT04346407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule daily starting with pre-op cocktail and continued twice daily for three days after surgery
Study NCT03744403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.
Study NCT03319316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Combination of durvalumab + tremelimumab treatment
Study NCT03319316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Combination of durvalumab + tremelimumab treatment
Study NCT02532257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02532257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02532257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02532257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03378245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral modification and education on pharmacologic treatments.
Description: Education and counseling of care-giving staff on behavioral modification strategies, as well as education about current standard of care best practices for pharmacologic interventions.
Study NCT01726062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus Incentives
Description: 1. Two hospital-based, face-to-face MI+ sessions~2. Two home-based MI+ sessions~3. Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge
Study NCT01726062 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional Care (CC)
Description: Participants in this arm will receive brochures and a brief information meeting in the NICU.
Study NCT02532062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 4,000 IU, oral, once a day for one year
Study NCT02532062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multivitamin
Description: oral, once a day for one year
Study NCT02532062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multivitamin
Description: oral, once a day for one year
Study NCT02532062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral, once a day for one year
Study NCT04498702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202 treatment
Description: A modified 3+3 design was employed: The dose was started at 300 mg and increased to 450 mg, 600 mg and 750 mg if there was no dose-limiting toxicity (DLT) in 3 subjects after 4-week consecutive administration of APL-1202. When the dose-escalation study was in progress, the doses for any newly enrolled subjects would be the starting dose or the highest dose confirmed with no DLT by the dose-escalation cohort at the time of enrollment. When the MTD or the 750 mg daily dose was attained as a safe dose, the dose for all subjects in the study or subsequently enrolled subjects would be MTD or 750 mg/day.
Study NCT00621257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol
Description: 8000 units/ml
Study NCT00621257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ergocalciferol
Description: 8000 units/ml
Study NCT00621257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 400 units per drop
Study NCT05076604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cardioplegia Solution
Description: The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood.